MAY 4, 2026 - ASAHI INTECC USA, Inc. announced thecommencement of a distribution agreement with QXMédical for the BoostingCatheter, which has been available in select regions globally and is nowentering the US market. ASAHI INTECC USA, Inc. will undertake distribution ofBoosting Catheter as of May 4, 2026.
Physicians utilize minimally invasive diagnostic andinterventional procedures in treating vascular issues, including blockages inblood vessels that can occur in the heart. The Boosting Catheter providesexcellent support to advance interventional devices in coronary proceduresincluding PCI and CTOs.
“The partnership with QXMédical demonstrates ourcommitment to equipping physicians with comprehensive tools essential foradvancing coronary interventions,” said Joe Wright, general manager at ASAHIINTECC USA. “The Boosting Catheter aligns with the guiding principles of theASAHI product portfolio to provide healthcare professionals a full range ofcutting-edge technologies and products to deliver the highest standard of care.This collaboration reflects our shared vision to drive innovation in thetreatment of coronary artery disease, ensuring that physicians have access tothe most effective, reliable, and advanced technologies to improve patientoutcomes.”
The QXMédical Boosting Catheter is the next generation ofguide extension catheters. This technology is designed for use with guide cathetersand sheaths to assist with delivery and exchange of interventional devices incoronary vessels. The Boosting Catheter offers exceptional trackability, aunique atraumatic tip design, large internal passageways to support complexprocedures, and French sizes 5.5 to 8. The Boosting Catheter is the only guideextension with clinical indication for delivery of procedural fluids.
“We are excited to bring the Boosting Catheter to the U.S.through our partnership with ASAHI INTECC USA. This collaboration marks apivotal moment in our growth strategy, allowing us to expand our footprint andbring this directly to American physicians. By joining forces with a respectedleader in the industry and leveraging ASAHI’s extensive network and deepunderstanding of the coronary intervention landscape, we are poised tosignificantly enhance the availability of the Boosting Catheter,” says FernandoDi Caprio, President and Chief Technology Officer at QXMédical. “Thispartnership exemplifies our ongoing commitment to advancing medical solutionsand strengthens our shared vision of improving healthcare outcomes across theU.S.”
The Boosting Catheter is manufactured by QXMédical, LLC. QXMédical,LLC is a U.S.-based medical device manufacturer headquartered in Saint Paul,Minnesota, focused on minimally invasive technologies for cardiovascular andperipheral interventions. The company designs and manufacturesphysician-focused solutions used in complex procedures worldwide.
ASAHI INTECC Co., Ltd. manufactures medical devices,industrial materials and innovative products with a unique and unprecedentedwire processing technology. ASAHI’ operations are spread across the U.S.,Europe, Singapore, China and Hong Kong and are headquartered in Seto, Japan.
ASAHI INTECC USA, Inc. is located in Irvine, California.For more information on ASAHI INTECC’s Medical products handled by ASAHI INTECCUSA, Inc., please visit us at asahi-inteccusa-medical.com.
